

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42

Trained dogs can detect the odour of Parkinson’s Disease

Nicola Rooney a,b*, Drupad K Trivedi^c, Eleanor Sinclair^c, Caitlin Walton Doyle^c, Monty Silverdale^d, Perdita Barran^c, Tilo Kunath^e, Steve Morant^f, Mark Somerville^a, Jayde Smith^a, Julie Jones-Diette^a, Jenny Corish^a, Joy Milne^c, Claire Guest^a

^a Medical Detection Dogs, 3 Millfield, Greenway Business Park, Winslow Road, Great Horwood, Milton Keynes, MK17 ONP.

^b Bristol Veterinary School, University of Bristol, BS40 5DU

^c Manchester Institute of Biotechnology, Department of Chemistry, The University of Manchester, 131 Princess Street, Manchester, UK, M1 7DN

^d Department of Neurology, Salford Royal Foundation Trust, Manchester Academic Health Science Centre, University of Manchester, Manchester, U.K., M6 8HD

^e Institute for Stem Cell Research, School of Biological Sciences, The University of Edinburgh, Edinburgh UK, EH16 4UU

^f Division of Molecular and Clinical Medicine, University of Dundee, DD1 4HN.

Running title: Dogs can detect the odour of Parkinson’s Disease

Correspondence address:

Animal Behaviour and Welfare Group, Bristol Veterinary School, Langford, UK. BS40 5DU

Tel : +44 (0) 117 455 0785 nicola.rooney@bristol.ac.uk

Abstract

A definitive diagnostic test for PD remains elusive, so identification of potential biomarkers may shed light on methods for diagnosis and facilitate early intervention. Excess sebum secretion and skin pathology are recognised symptoms of early PD. It is likely these result in a unique signature of volatile organic compounds that could be used to identify early stages of disease. Numerous medical conditions produce distinctive odours, and dogs have been trained to detect many of these. A single previous study, suggested that dogs can also be trained to detect Parkinson’s Disease. In this study, two dogs were trained to distinguish sebum swabs obtained from drug naïve, and medicated Parkinson’s patients from swabs from control participants. After 38-53 weeks of training on 205 samples (90 target and 115 control), the dogs were tested in a double-blind trial using 60 control and 40 target samples from drug-naïve patients. The dogs both showed high sensitivity (proportion of target samples found 70% and 80%) and specificity (proportion of control samples not alerted to 90% and 98%) of alerting response. This trial supports previous findings that dogs can be trained to reliably detect the odour of PD. We suggest there is a potential for dogs to achieve even higher accuracy with increased exposure and refined training methods and to detect early stage PD, even

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

43 prior to diagnosis, as well as hard to diagnose PD cases. Further exploration of the factors which
44 affect dogs' sensitivity and specificity and sample features which affect accuracy of discrimination
45 are now required.

46
47 Keywords: dogs, sensitivity and specificity

48 Introduction

49 Parkinson's disease (PD) is a neurological disease that causes progressive motor symptoms including
50 tremor, stiffness and slowness of movement, as well as non-motor symptoms including mood
51 problems, cognitive issues, sleep disturbance and pain. Neurodegeneration, predominantly in the
52 central nervous system is the cause to these widespread symptoms. At Braak stage 3, the Substantia
53 Nigra becomes affected, leading to a reduction in dopamine production in the brain, a chemical that
54 is vital for the control of movement^{Error! Reference source not found.}. As progression of the disease can be
55 slow, often with only very minor symptoms initially, it is difficult to definitively diagnose PD
56 particularly in the early stages. Early motor and non-motor symptoms, may result in people being
57 diagnosed with a range of other conditions including rheumatological, neurological, sleep and mood
58 disorders². Even as the disease progresses, it can be difficult to differentiate from other Parkinsonian
59 disorders³. Early and accurate diagnosis is vital, to allow patients to benefit from pharmacological
60 interventions, such as a levodopa/carbidopa, which may be more effective when administered
61 early⁴. Non-pharmacologic interventions, such as exercise, are also easier for the patient to perform
62 before declines in locomotor skills and movement occur⁴.

63 Around 1 in 500 people in the UK are affected by PD, a prevalence of approximately 127,000 in 2017
64 ⁵. Gumber et al. (2017) suggests an economic burden to the NHS of £2,118 per person with
65 Parkinson's (PwP), hence the total UK annual cost could be in excess of £268 million per year ⁵. With
66 an aging population and rising demand for health services, this will create a significant challenge for
67 healthcare providers. Research is needed to support treatment decisions, direct prevention
68 strategies, raise awareness, and avoid unnecessary and expensive repeat admissions between home
69 and hospital.

70 Studies that aid our understanding of early symptoms could help develop early diagnosis are
71 paramount. Much research has attempted to identify new biomarkers⁶, particularly those that may
72 predict whether someone will develop PD in the future.⁷ One early non-motor symptom, is
73 seborrheic dermatitis: excessive sebum (waxy or oily secretion) which is excreted from the
74 sebaceous glands at higher quantities in patients with PD ^{8,9}. Sebum has been noted to have a very
75 distinctive odour identified in repeated blinded studies with human super-smeller Joy Milne, who
76 has hyperosmia. This could potentially be used as an indicator for the disease ¹⁰ and is associated
77 with lipid dysregulation consistent with many PD studies¹¹.

78 Many medical conditions have distinctive odours ^{12,13} including cancer ¹⁴ and schizophrenia ^{15,16}.
79 Health care workers have reportedly used scent to triage illness, and in studies as early as 1960,
80 when it was shown that sweat from schizophrenic and non-schizophrenic patients could be
81 distinguished by trained rats using odour alone¹⁷. There is a growing body of evidence that disease-
82 specific volatile organic compounds (VOCs) could be used for the early detection of disease before
83 more obvious clinical signs or symptoms become apparent¹⁸. The mechanism for the release of
84 volatiles is not well studied and varies with disease. However, small amounts of volatile organic
85 compounds are released through metabolic processes and can be identified in the secretions of
86 sweat, mucus, sebum, urine, blood and breath ¹⁹.

87 The olfactory capability of dogs to detect diseases is well-established²⁰. For over twenty years, the
88 UK charity Medical Detection Dogs (MDD) has trained dogs to detect human diseases ranging from
89 prostate cancer²¹ to malaria²² and Covid-19^{e.g. 23}. MDD has also trained assistance dogs to alert to
90 the onset of life-threatening episodes for people living with chronic diseases such a Type 1 diabetes
91²⁴⁻²⁵. It therefore seems extremely plausible that dogs could be trained to alert to the odour of PD.

92 A recent prospective, diagnostic case-control study was conducted in China²⁸. Three dogs trained in
93 a laboratory were tested on sebum samples from PD medicated and drug naïve patients, and
94 matched controls. The diagnostic criterion applied was that at least two of the three dogs alerted to
95 the sample and, using this criteria, the study saw sensitivity and specificity rates of 91% and 95% to
96 medicated and 89% and 86% to drug naïve samples, respectively. The authors concluded that
97 trained dogs could be a useful, quick non-invasive and cost-effective method to identify patients
98 with PD during community screening and health check-ups as well as within neurological practice,
99 but provide limited information on the dog's training and testing.

100 In the current study, we further tested the capacity of trained dogs to discriminate the odour of
101 Parkinson's disease from controls using sebum swabs. Since the dog is effectively the measuring
102 instrument, it is important to provide full details of its training, calibration and testing which we
103 describe fully. To simulate real operations, unlike Gao et al²⁸, we did not use precisely matched
104 control samples. However, since it is vital to minimise all possible confounding factors^{e.g. 29} we
105 trained the dogs using samples taken from drug naïve (DN) patients shortly after diagnosis and a
106 control group ranging from healthy individuals to patients with other neurological conditions. We
107 started with ten potential dogs, and based on their performance during initial training, we selected
108 two dogs, which were trained by a professional dog trainer (MS) using an established protocol²¹ and
109 then tested during double-blind trials.

110

111 Materials and Methods

112

113 Ethical Review

114 Ethical approval for this project (IRAS project ID 191917) was obtained by the NHS Health Research
115 Authority (REC reference: 15/SW/0354).

116

117

118 Participant Recruitment

119 Parkinson's disease patient and control participant samples were collected during a nationwide
120 recruitment at 25 different NHS clinics as described in Trivedi et al.¹⁰. The participants for the
121 current study were selected at random from those collected for that study, in order to match
122 phenotypes as closely as possible for both training and testing. Those used for testing were all drug
123 naïve, whilst medicated patients were also used in the latter stages of training. The control samples
124 were collected from people accompanying PwP in clinics at the same sites and additional control
125 samples came from volunteers attending the Medical Detection Dog centre.

126

127 Sample collection

128 All participants were asked to avoid showering, use of cosmetics and fragrances for 24 hours prior to
129 sample collection to minimise contamination from washing cosmetics. Sampling followed the same
130 standard operating procedure for disease and control study volunteers. Sebum was sampled from
131 volunteers by wiping a square piece of medical gauze along the hairline, down the nape of the neck
132 and across the shoulder, this was performed by a clinician for samples taken in NHS clinics and by
133 the volunteer themselves for other controls. The upper trunk was selected as it is a sebum rich
134 location and during pilot method development studies, this area was indicated by human super
135 smeller to have highest odour linked to PD¹⁹. The gauze samples were bagged individually and
136 sealed in an airtight, minimal odour, plastic bag which was labelled with the participants'
137 anonymised code. Samples were shipped to a central Manchester facility and stored at -80°C within
138 24 hours of arrival.

139 From here the samples were transported on dry ice to the dog training centre accompanied by a
140 recruitment cohort code, participant sex, age, BMI, ethnicity, medical conditions, current
141 medications, drinking and smoking behaviour (obtained from a questionnaire that participants filled
142 in at the time of sampling) and whether they were a control or patient. For patients, further
143 information was provided on date of diagnosis, and medications they were taking for PD. All samples
144 were stored at -80 °C.

145 In total, 130 samples were collected from PD patients and 175 from control and these were
146 randomly divided into 105 training and 100 testing samples. All samples were cut in half ahead of
147 storage. Duplicate samples were either both used within the training samples, or one was used as a
148 training sample, and the other as a "filler" control during testing, to enable lines of four samples to
149 be presented but the dogs' response to any "familiar" samples during testing was not analysed. The
150 training samples were labelled as positive or control, but the test samples were given only a code, so
151 testing was totally blind.

152 Canine Disease Detection Training

153 After initial screening of ten dogs, five were deemed to have potential aptitude and hence
154 commenced initial PD training.

155 A training protocol was used which increased in difficulty over time. In Phase 1, the target scent was
156 introduced to the dog, and the dog rewarded for showing a behavioural change in response.
157 Individual dogs naturally show different behaviours, and these were rewarded by their trainers, so
158 each dog gave a consistent behaviour e.g., sit or stand and stare, thereafter terms an indication.
159 Correct responses were rewarded with food or ball-play, in conjunction with the use of an audible
160 clicker (used as a secondary reward).

161 Initial training used search and find games, then dogs were trained to walk along a line of four
162 stainless steel stands, one metre apart, each with an arm holding a 40 ml glass jar containing a swab
163 sample. A stainless-steel grill was placed over the mouth of each jar to prevent the dog touching the
164 sample. After each line was searched, the plates were cleaned in an ultrasonic cleaner with an
165 enzymatic solution (Reprozyme TM, NVS Stoke-on- Trent UK), the plates were rinsed thoroughly
166 using a commercial glass washer (minimum 85 °C) then left to air dry to avoid any contamination.
167 The jars were cleaned in the same way but additionally were placed in an oven at 180-C for 20
168 minutes.

169 The dog was trained to sniff each of the four stands in order. Their behaviour at each stand was
170 recorded on a database as IND (indicated), HES (hesitated), INT (interest, but weaker than HES), NI

171 (no interest) or NS (not searched, usually because a sample earlier in the line was indicated). Initially
172 dogs were presented with one positive sample and three control samples during each run. As
173 training progressed, lines with four controls were also presented. Dogs were rewarded for both
174 indicating positive target samples and for searching a negative line without an indication. Once dogs
175 were reliably indicating positive target samples against control samples taken from participants with
176 non-neurological conditions, we added control samples taken from patients with diseases with
177 similar symptoms to Parkinson's disease, including depression, anxiety, bi-polar disorder, epilepsy,
178 stroke, hypothyroidism and migraine. Later training also included medicated (as well as drug naïve)
179 target samples to ensure dogs were discriminating entirely based on PD status.

180 As training progressed, three of the dogs failed to learn the task, and hence were rejected from
181 training. Only the data from the two remaining dogs is presented here. They were a two-year old
182 male Golden Retriever (Dog 1) and a three-year old male Labrador x Golden Retriever (Dog 2).

183 In total, we used 205 samples during training; 90 targets and 115 controls. Dog 1 took part in 72
184 training sessions over 38 weeks and encountered control samples on 1683 occasions and target
185 samples on 597 occasions. Dog 2 took part in 83 sessions over 53 weeks and encountered control
186 samples on 1759 occasions and target samples on 582 occasions. Each training session lasted an
187 average of 21 minutes and a maximum of 69 minutes. On three occasions during training, both dogs
188 indicated in response the same control sample, and in these cases the sample was withdrawn from
189 the training process.

190

191 Canine Disease Detection Testing

192 The two dogs that were deemed to have learnt the task adequately, proceeded to a double-blind
193 randomised controlled trial and were presented with 100 previously unseen samples, of which 40
194 were from individuals with confirmed disease (positive for PD). Due to the scarcity of controls, we
195 used an additional 100 duplicates of control samples seen by the dogs during training. These were
196 used as "fillers" to facilitate presenting lines of four samples, but the dogs' responses to these
197 familiar samples were not included in any analyses.

198 The samples were presented in the same way as during training in a four-stand alignment. In each
199 "run" there was either one or no positive samples. Both the trainer/handler and the experimenter
200 were blind to the presence and position of any targets. Ten control and five positive samples from
201 the training set were used for calibration runs, to confirm the dog was focused on the scent.
202 Calibration runs were requested at any time by the trainer, were unblinded and their results were
203 not included in the analysis.

204 The regular trainer guided the dog to search each line of samples. Dogs were permitted to make a
205 maximum of four passes over the line. Once the handler was confident of the dog's choice, a
206 decision was communicated to the experimenter. For each the dogs' behaviour was coded as it was
207 during training (IND, HES, INT, NI or NS), with HES, INT and NI all being treated as a negative
208 response for analysis.

209 Each line of samples was presented in reverse order on a second occasion, so that samples for which
210 no decision was made in the first run re-presented. Any samples that were still not seen after this
211 run were collected together in new lines, until a decision had been made for all samples. This
212 process resulted in some samples being encountered more than once by the same dog, however we
213 only analysed their response on first encounter.

214

215 Data Management and Analysis

216 A blinded experimenter entered the responses to each sample into the database. All trial samples
217 had previously been given a “blind ID” which was read by the data collection software to determine
218 whether responses were correct. The software revealed whether each response was correct, and if
219 so, the trainer was asked to reward their dog. If any sample was incorrect, no reward was given. The
220 database was password protected and only the trial statistician (SM) knew both passwords prior to
221 trial completion.

222 We used the first encounter with each of the 100 novel samples to calculate sensitivity (proportion
223 of target samples found) and specificity (proportion of control samples that were not alerted to) for
224 each dog. We also tested whether there was any association between the errors made by each dog,
225 examining target and control samples separately using Fishers Exact tests.

226

227 Results

228 Training

229 The performance of two dogs during training was deemed satisfactory. In its last 10 training sessions
230 Dog 1 responded correctly to 91% of encounters and Dog 2 responded correctly to 90% of
231 encounters.

232

233 Testing

234 Both dogs demonstrated an ability to discriminate between the PD positive and control samples they
235 had not encountered before ($P < 0.0001$), with sensitivities of 70.0% and 80.0% and specificities of
236 90.0% and 98.3% (Table 1).

237

238 Table 1. Sensitivity and specificity of two dogs in double-blind trials

239

	Samples		Indications		Sensitivity and specificity with confidence intervals (%)
	Type	<i>n</i>	Number indicated	% indicated (as PD)	
Dog 1	Control	60	6	10.0	Specificity 90.0 (79.5, 96.2)
	Positive	40	28	70.0	Sensitivity 70.0 (53.5, 83.4)
			$p < 0.0001$		
Dog 2	Control	60	1	1.7	Specificity 98.3 (91.1, 100.0)
	Positive	40	32	80.0	Sensitivity 80.0 (64.4, 91.0)
			$p < 0.0001$		
<i>p</i> -values for Fisher’s exact tests for testing the difference in indication rates between target and control samples.					

240

241 Agreement between the two dogs was higher than expected by chance for positive samples: 7 were
 242 missed by both dogs (expected 2.4) and 27 were indicated by both dogs (expected 22.4). Agreement
 243 between the dogs for control samples was close to expectation.

244 Table 2. Agreement between responses of the two dogs during double blind testing p-values for
 245 Fisher's exact tests. Numbers in brackets are the expected numbers if there were no correlation
 246 between the dogs' responses.

Indicated by Dog 1

Positive samples	Indicated by Dog 2		No	Yes	Total
		No	7 (2.4)	1(5.6)	8
		Yes	5 (9.6)	27 (22.4)	32
		Total	12	28	40

247

$p=0.0003$

Control samples	Indicated by Dog 2		No	Yes	Total
		No	54 (53.1)	5 (5.9)	59
		Yes	0 (0.9)	1 (0.1)	1
		Total	54	6	60

$p=0.1000$

248 Discussion

249 This study confirms the previous findings of Gao et al²⁸ that dogs can be trained to discriminate
 250 between Parkinson's patient and control sebum swab samples. Although only two dogs from the
 251 initial ten trialled were deemed suitable to progress to full training, the subsequent performance of
 252 these during training and double-blind testing demonstrates that it is possible for dogs of the correct
 253 aptitude to learn the task.

254 The two dogs achieved high sensitivity and specificity, when trained using ex-situ sebum samples,
 255 showing there is an olfactory signature which is different in patients with Parkinson's Disease. Since
 256 increased sebum secretion has also been noticed before motor signs of PD^{30,31} this suggests that
 257 detection of biomarkers in sebum could lead to early diagnosis and intervention.

258 Agreement between dogs was higher than would be expected by chance, suggesting that some
 259 samples were easier to identify than others. There were several samples to which both dogs
 260 incorrectly indicated. Although initial inspection of sample details suggested no obvious
 261 commonalities between these samples, further research is required to understand which features of
 262 the sample are responsible for these differences.

263 Sensitivity levels of 70 and 80% are high; well above chance and comparable to levels seen for
 264 example in malaria detection²², and considerably higher than those obtained when using dogs to
 265 detect some other medical conditions (e.g., 41% bladder cancer²¹). The only other study examining
 266 detection of PD by dogs, obtained higher sensitivity (91%), but similar specificity (95%) as seen here
 267 (98% and 90%).

268 There are multiple plausible reasons for the difference in sensitivity between the two studies; Gao et
 269 al²⁸ used consensus responses of two out of three dogs as the detection criterion²⁸ whilst our
 270 analysis took each of two dog's responses individually. Gao's testing protocol used PD samples and

271 six perfectly matched controls, whilst ours included controls that were not precisely matched which
272 may make the task harder for the dogs, but we deem this to be more authentic. Gao et al also
273 presented a known PD target to the dogs ahead of each testing run so dogs were able to “match to
274 source”, which may improve their detection but may not be practicable in an operational setting.
275 The value of this procedure is yet to be determined and is an important area of future study. Gao’s
276 dogs had been trained on PD over a period of two years, whilst ours were trained for less than a
277 year, although the number of samples encountered during training was not described by the Gao at
278 al., so cannot be compared. There were several other details of the dog testing methods which were
279 not described by Gao et al., such as the period over which testing occurs, or a description of the
280 “tanks” in which samples were presented, which precluding further comparisons. However, the
281 studies together suggest that refinements to training and sample presentation in the future could
282 lead to further increases in detection accuracy.

283 In our study, whilst the specificity of Dog 2 was 98% reflecting very few false alerts, and similarly the
284 dog showed the highest sensitivity (80%), Dog 1 showed slightly lower specificity (90%) and a
285 sensitivity of only 70%. These differences may reflect personality differences between the two dogs,
286 with Dog 1 showing a more liberal approach to responding; a higher tendency for false alarms thus
287 minimising false negatives to increase the chance of a hit³². Or it may reflect subtle differences in
288 their training, leading Dog 2 to be more precise in its responses. Further analysis using the data
289 stored during training, will enable understanding of the extent to which these individual differences
290 develop or are consistent from early training.

291 In conclusion, the sensitivity and specificity of dogs trained to find PD positive samples is
292 encouraging and supports previous finding that further research has the potential to help develop
293 methods for the early diagnosis of PD, by dogs or by other technology. This may in turn lead to
294 opportunities for earlier intervention than is possible at present and be especially beneficial for hard
295 to diagnose cases of PD. Longitudinal studies of dogs’ capacity to alert prior to formal diagnosis are
296 now required.

297

298 Acknowledgements including source of funding

299 We thank Michael J Fox Foundation and Parkinson’s UK for funding this study. We also thank the
300 nationwide NIHR recruitment centres for their support and would like to thank the patient’s carers
301 and participants for providing the samples. We are very grateful to all the participants who took part
302 in this study.

303

304 Conflict of Interest

305 The authors have no conflict of interest to report.

306

307 Author contributions statement

308 CG, PB, MS and TK conceived the study. CG, JC, KW designed the experiments. CG, and PB supervised
309 the study. DT., ES., CWD, JM., and PB performed or contributed to the sample collection and
310 preparation. MS performed the dog sample preparation, dog training and data collection, with
311 assistance from JS. SM performed statistical analysis. NJR wrote the manuscript, with input from
312 JJD. All authors commented and contributed to the final version of manuscript.

313
314

315 Data availability

316 The data supporting the findings of this study are openly available at the University of Bristol data
317 repository, data.bris, at <https://doi.org/10.5523/bris.2ffiar75hr0b82otk9axxh44i>

318

319

320 References

- 321 1. Kalia LV, Lang AE (2015) Parkinson's disease. *Lancet*. 2015 Aug 29;386(9996):896-912. doi:
322 10.1016/S0140-6736(14)61393-3. PMID: 25904081.
- 323 2. Ali K, Morris HR (2015) Parkinson's disease: chameleons and mimics. *Practical*
324 *neurology*, 15(1), pp.14-25.
- 325 3. Schootemeijer S, van der Kolk NM, Bloem BR, de Vries NM (2020) Current Perspectives on
326 Aerobic Exercise in People with Parkinson's Disease. *Neurotherapeutics* 17, 1418–1433
327 <https://doi.org/10.1007/s13311-020-00904-8>
- 328 4. Joutsa J, Gardberg M, Røyttä M, Kaasinen V. Diagnostic accuracy of parkinsonism syndromes by general
329 neurologists. *Parkinsonism & Related Disorders*. 2014 Aug;20(8):840-844. DOI:
330 10.1016/j.parkreldis.2014.04.019. PMID: 24816002
- 331 5. Gumber A, Ramaswamy B, Ibbotson R, Ismail M, Thongchundee O, Harrop D, Allmark P, Rauf
332 A (2017) Economic, Social and Financial Cost of Parkinson's on Individuals, Carers and their
333 Families in the UK. Project Report. Centre for Health and Social Care Research, Sheffield
334 Hallam University.
- 335 6. He R, Yan X, Guo J, Xu Q, Tang B, Sun Q (2018) Recent Advances in Biomarkers for
336 Parkinson's Disease. *Frontiers in aging neuroscience*, 10, 305.
- 337 7. Del Tredici K, Braak H. Review: sporadic Parkinson's disease: development and distribution
338 of alpha-synuclein pathology. *Neuropathol Appl Neurobiol*. 2016 Feb;42(1):33-50. doi:
339 10.1111/nan.12298.
- 340 8. Krestin D (1927) The Seborrhoeic Facies as a Manifestation of Post-Encephalitic
341 Parkinsonism and Allied Disorders. *QJM*, os-21 (81), 177–186. 10.1093/qjmed/os-21.81.177.
- 342 9. Ravn Jørgensen A.-H, Thyssen JP, Egeberg A (2017) Skin disorders in Parkinson's disease:
343 potential biomarkers and risk factors. *Clin., Cosmet. Invest. Dermatol.* 2017, 10, 87–92.
344 10.2147/CCID.S130319.
- 345 10. Trivedi DK, Sinclair E, Xu Y, Sarkar D, Walton-Doyle C, Liscio C, Banks P, Milne J, Silverdale M,
346 Kunath T, Goodacre R (2019) Discovery of volatile biomarkers of Parkinson's disease from
347 sebum. *ACS Central Science*, 5(4), pp.599-606.
- 348 11. Sinclair E, Trivedi DK, Sarkar D, Walon-Doyle C., Milne J, Kunath T, Rijis AM, de Bie RMA,
349 Goodacre R, Silverdale M, Barran P. (2021) Metabolomics of sebum reveals lipid
350 dysregulation in Parkinson's disease. *Nat Commun* 12, 1592 .
- 351 12. Cone TE (1968) Diagnosis and treatment: some diseases, syndromes and conditions
352 associated with an unusual odour. *Pediatrics*, Springfield, 41, 993.
- 353 13. Liddell K Smell as a diagnostic marker. (1976) *Postgrad Med J*, 52(605):136-138, 01 Mar 1976
- 354 14. Liddell K, White JE (1975) The smell of cancer. *British Journal of Dermatology*, 92, 215.
- 355 15. Brass A (1970) Odour of sanity. *Journal of the American Medical Association*, 212, 472.

- 356 16. Smith K, Thompson GF, Koster HD (1969) Sweat in schizophrenic patients: identification of
357 the odorous substance. *Science*, 166, 398
- 358 17. Smith K, Sines JO (1960) Demonstration of a peculiar odor in the sweat of schizophrenic
359 patients. *Archives of General Psychiatry*, 2, 184.
- 360 18. Pirrone F, Piotti P, Galli M, Gasparri R, La Spina A, Spaggiari L, Albertini M (2023) Sniffer dogs
361 performance is stable over time in detecting COVID-19 positive samples and agrees with the
362 rapid antigen test in the field. *Scientific Reports*, 13(1).
- 363 19. Trivedi DK, Sinclair E, Xu Y, Sarkar D, Walton-Doyle C, Liscio C, Banks P, Milne J, Silverdale M,
364 Kunath T, Goodacre R (2019) Discovery of volatile biomarkers of Parkinson's disease from
365 sebum. *ACS Central Science*, 5(4), pp.599-606
- 366 20. Rooney N (2016) A medical detection role for dogs *International Animal Health*
367 *Journal*. 3, 4, 42
- 368 21. Willis CM, Church SM, Guest CM, Cook WA, McCarthy N, Bransbury AJ, Church MRT, Church
369 JT (2004) Olfactory detection of human bladder cancer by dogs: proof of principle study. *BMJ*
370 329: 712.
- 371 22. Guest C, Pinder M, Doggett M, Squires C, Affara M, Kandeh B, Dewhirst S, Morant SV,
372 D'Alessandro U, Logan JG., Lindsay SW (2019) Trained dogs identify people with malaria
373 parasites by their odour. *The Lancet Infectious Diseases*, 19(6): .578-580.
- 374 23. Vesga O, Agudelo M, Valencia-Jaramillo AF, Mira-Montoya A, Ossa-Ospina F, Ocampo E,
375 Čiuoderis K, Pérez L, Cardona A, Aguilar Y, Agudelo Y, Hernández-Ortiz JP, Osorio JE (2021)
376 Highly sensitive scent-detection of COVID-19 patients in vivo by trained dogs. *PLoS One*.
377 16(9):e0257474. doi: 10.1371/journal.pone.0257474. PMID: 34587181; PMCID:
378 PMC8480816.
- 379 24. Rooney NJ, Morant S, Guest C (2013) Investigation into the Value of Trained Glycaemia Alert
380 Dogs to Clients with Type I Diabetes *PLoS ONE*. 10.1371/journal.pone.0069921
- 381 25. Rooney N, Guest C, Swanson L, Morant S (2019) How effective are trained dogs at alerting
382 their owners to changes in blood glycaemic levels? Variations in performance of glycaemia
383 alert dogs *PLoS ONE*. 14, 1, 16 p., e0210092.
- 384 26. Wilson CH, Kane S, Morant SV, Guest CM, Rooney NJ (2020) Diabetes Alert Dogs: objective
385 behaviours shown during periods of owner glucose fluctuation and stability *Appl Anim Behav*
386 *Sci*. 223, 10 p., 104915.
- 387 27. Wilson C, Morant S, Kane S, Pesterfield C, Guest C, Rooney NJ. (2019) An Owner-
388 Independent Investigation of Diabetes Alert Dog Performance *Frontiers in Veterinary*
389 *Science*.
- 390 28. Gao CQ, Wang SN, Wang MM, Li JJ, Qiao JJ, Huang JJ, Zhang XX, Xiang YQ, Xu Q, Wang JL, Liu
391 ZH, Wang JG, Chen ZH, Hu PA, Song Z, Gu SJ, Zhang RX, Lei LF, Zhan KB, Long YT, Zhang Y, Ye
392 M, Zhong Z, Liu YB, Zhang C, He ZM, Fang X, Peng JG, Wang CY, Xu H, Xia BH, Shen L, Tang BS,
393 Zheng CW, Li YA, Guo JF (2022) Sensitivity of Sniffer Dogs for a Diagnosis of Parkinson's
394 Disease: A Diagnostic Accuracy Study. *Mov Disord*. 37(9):1807-1816. doi:
395 10.1002/mds.29180.
- 396 29. Guest C, Harris R, Anjum I, Concha A, Rooney NJ (2020) A lesson in standardisation -subtle
397 aspects of the processing of samples can greatly affect dogs' learning: subtle aspects of the
398 processing of samples can greatly affect dogs' learning *Frontiers in Veterinary Science*.
- 399 30. Pochi PE, Strauss JS, Mescon H (1962). Sebum production and fractional 17-ketosteroid
400 excretion in parkinsonism. *J. Invest. Dermatol*. **38**, 45–51
- 401 31. Burton JL, Cartlidge M, Cartlidge NEF Shuster S (1972) Sebum excretion in Parkinsonism.
402 *British Journal of Dermatology* **88**, 263–266

- 403 32. Gadbois S, Reeve C (2016). The semiotic canine: scent processing dogs as research assistants
404 in biomedical and environmental research. *Dog Behaviour*, 2, 26–32. DOI:
405 <http://dx.doi.org/10.4454/db.v2i3.43>